Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$1.2 billion.

  • Zentalis Pharmaceuticals' Retained Earnings fell 1482.89% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 1482.89%. This contributed to the annual value of -$1.1 billion for FY2024, which is 1866.39% down from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Retained Earnings stood at -$1.2 billion for Q3 2025, which was down 1482.89% from -$1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Retained Earnings peaked at -$418.6 million during Q1 2022, and registered a low of -$1.2 billion during Q3 2025.
  • Moreover, its 4-year median value for Retained Earnings was -$878.5 million (2024), whereas its average is -$832.4 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Retained Earnings tumbled by 5854.66% in 2023, and later tumbled by 1482.89% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Retained Earnings (Quarter) stood at -$596.4 million in 2022, then plummeted by 49.0% to -$888.6 million in 2023, then dropped by 18.66% to -$1.1 billion in 2024, then dropped by 9.66% to -$1.2 billion in 2025.
  • Its last three reported values are -$1.2 billion in Q3 2025, -$1.1 billion for Q2 2025, and -$1.1 billion during Q1 2025.